Want to see SE:SYNACT full AI Analyst Report?
SynAct Pharma AB (SYNACT) AI Stock Analysis
SynAct Pharma AB
(Nasdaq OMX AB:SYNACT)
Financial performance is the primary driver with a moderate score as strong balance sheet offsets weak income and cash flows. Positive technical indicators add support while valuation is limited by negative earnings.
SynAct Pharma AB (SYNACT) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 911.79M
- Dividend Yield
- ―
- Average Volume (3M)
- 140.62K
- Price to Earnings (P/E)
- -8.2
- Beta (1Y)
- -0.07
- Revenue Growth
- ―
- EPS Growth
- 1.42%
- Country
- Sweden
- Employees
- 8
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
SynAct Pharma AB Business Overview & Revenue Model
Company Description
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently bei...
How the Company Makes Money
SynAct Pharma is a clinical-stage biopharmaceutical company and, based on publicly available information, it does not appear to have a marketed product generating recurring commercial sales; therefore, its business model is primarily funding-driven a...
SynAct Pharma AB Financial Statement Overview
Summary
Weak income statement and cash flow due to zero revenue and high operational burn, offset by a solid balance sheet with minimal debt providing financial runway.
Income Statement
25NegativeBalance Sheet
78PositiveCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | -617.00K | -778.00K | -1.06M | -88.00K |
| EBITDA | -112.72M | -116.52M | -89.36M | -148.14M | -105.75M | -76.62M |
| Net Income | -106.14M | -110.83M | -82.40M | -215.81M | -99.20M | -69.30M |
Balance Sheet | ||||||
| Total Assets | 208.24M | 220.52M | 270.52M | 228.02M | 142.60M | 38.37M |
| Cash, Cash Equivalents and Short-Term Investments | 14.23M | 53.41M | 61.21M | 62.40M | 108.25M | 24.00M |
| Total Debt | 929.00K | 1.81M | 1.88M | 637.00K | 2.06M | 3.09M |
| Total Liabilities | 36.57M | 50.23M | 56.35M | 51.83M | 16.08M | 17.50M |
| Stockholders Equity | 171.67M | 170.29M | 214.17M | 176.19M | 126.52M | 20.87M |
Cash Flow | ||||||
| Free Cash Flow | -82.67M | -97.33M | -89.20M | -100.18M | -117.56M | -65.00M |
| Operating Cash Flow | -117.21M | -97.33M | -89.20M | -100.18M | -117.56M | -65.00M |
| Investing Cash Flow | -13.89M | 0 | 0 | 370.00K | 27.00K | -6,000 |
| Financing Cash Flow | 77.01M | 90.46M | 87.41M | 53.98M | 200.71M | 74.32M |
SynAct Pharma AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SYNACT, the sentiment is Negative. The current price of 16.22 is below the 20-day moving average (MA) of 17.16, below the 50-day MA of 17.98, and below the 200-day MA of 17.90, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 35.54 is Neutral, neither overbought nor oversold. The STOCH value of 17.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SYNACT.
SynAct Pharma AB Peers Comparison
Overall Rating
SE:CANTA70Outperform
SE:HNSA55Neutral- SE:SYNACT53Neutral
SE:BINV43Neutral
SE:ACTI42Neutral
SE:FLERIE40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SE:CANTA | 70Outperform | SEK 451.68M | 2.35 | 63.09% | ― | ― | ― |
| SE:HNSA | 55Neutral | SEK 4.00B | -5.00 | ― | ― | -3.57% | 8.84% |
| SE:SYNACT | 53Neutral | SEK 911.79M | -8.23 | -58.12% | ― | ― | 1.42% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SE:BINV | 43Neutral | SEK 357.32M | -0.73 | -128.54% | ― | -83.67% | -50.29% |
| SE:ACTI | 42Neutral | SEK 105.31M | -10.14 | -93.01% | ― | ― | 54.60% |
| SE:FLERIE | 40Underperform | SEK 1.27B | -1.16 | -28.79% | ― | -172.86% | -251.31% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:SYNACT | SynAct Pharma AB | 16.22 | -7.18 | -30.68% | |
| SE:HNSA | Hansa Biopharma | 39.34 | 8.34 | 26.90% | |
| SE:BINV | BioInvent International AB | 5.43 | -28.47 | -83.98% | |
| SE:FLERIE | InDex Pharmaceuticals Holding AB | 13.90 | -21.10 | -60.29% | |
| SE:ACTI | Active Biotech AB | 4.00 | -2.42 | -37.76% | |
| SE:CANTA | Cantargia AB | 1.60 | -1.97 | -55.13% |
SynAct Pharma AB Corporate Events
SynAct Pharma seals first resomelagon dengue partnership in Brazil
SynAct Pharma has signed its first commercial partnership for resomelagon with Brazilian drugmaker Hipolabor Farmacêutica, targeting the vast dengue market in Brazil, where over a million patients seek care annually. The deal leverages Hipolabor...
SynAct Pharma Launches Global Investor and Partnering Push
SynAct Pharma plans an active presence at several investor and partnering conferences across Europe, the U.S., and Japan in September and October 2026. Chief executive Jeppe Øvlesen and chief business officer Mads Bjerregaard will present the co...
WHO Endorses SynAct Pharma’s Resomelagon as Key Dengue Drug Candidate
The World Health Organization has named SynAct Pharma’s oral pro-resolution therapy resomelagon as one of just six dengue drug candidates with sufficient efficacy data to merit further clinical development, and the only host-directed therapy am...
SynAct Pharma bolsters resomelagon data as it readies Phase 3 and weighs strategic deals
SynAct Pharma has released further analysis from its Phase 2b ADVANCE study of resomelagon in treatment-naïve rheumatoid arthritis patients, reinforcing earlier positive EXPAND data and supporting Phase 3 development. The company plans to refine...
SynAct Pharma Executives Sell Shares to Cover Danish Tax Liabilities
SynAct Pharma has disclosed that its chief executive officer, Jeppe Øvlesen, and chief scientific officer, Thomas Jonassen, have sold portions of their shareholdings in the company. The disposals were executed via their associated entities, Quan...
SynAct Pharma Expands Resomelagon’s Potential With New Preclinical Inflammation Data
SynAct Pharma will present new preclinical data on its Phase 3-ready resomelagon candidate at the 17th World Congress of Inflammation 2026 in Brazil, highlighting a distinct pro-resolution mechanism of action for inflammatory and infectious diseases....
SynAct Pharma Details 2026 First-Half Progress in Inflammatory Disease R&D
SynAct Pharma has released its interim report for January to June 2026, highlighting research and development progress in inflammatory diseases and providing operational and financial updates to stakeholders. The report underscores the company’...
SynAct Pharma strikes first resomelagon commercial deal in Brazil’s dengue market
SynAct Pharma has signed a term sheet with Brazilian drug maker Hipolabor Farmacêutica for a co-development and commercialization partnership around resomelagon to treat dengue and other viral infections in Brazil. The structure allows SynAct to...
SynAct Pharma Wins Key US Patent Ruling on Resomelagon Tablet Formulation
SynAct Pharma AB has secured a favorable ruling from the U.S. Patent Trial and Appeal Board on a patent application covering an immediate-release tablet formulation of its lead drug candidate, resomelagon. The decision confirms that developing a rapi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 21, 2026